2019 tables: Institutions - life sciences - corporate

The 2019 tables are based on Nature Index data from 1 January 2018 to 31 December 2018.

Table criteria

# Institution Share 2017 Share 2018 Count 2018 Change in Adjusted Share 2017-2018*
1 F. Hoffmann-La Roche AG, Switzerland 37.39 44.10 110 9.6%
2 Novartis International AG, Switzerland 30.73 27.30 93 -17.4%
3 AstraZeneca plc, United Kingdom (UK) 18.93 19.79 83 -2.8%
4 Amgen Inc., United States of America (USA) 10.72 15.21 58 32.0%
5 Alphabet Inc., United States of America (USA) 4.48 13.77 37 185.8%
6 GlaxoSmithKline plc. (GSK), United Kingdom (UK) 9.94 11.51 68 7.7%
7 Pfizer Inc., United States of America (USA) 10.60 11.32 44 -0.7%
8 Merck & Co., Inc., United States of America (USA) 13.07 7.70 33 -45.2%
9 Regeneron Pharmaceuticals, Inc., United States of America (USA) 4.95 6.00 17 12.7%
10 IBM Corporation, United States of America (USA) 4.09 5.16 24 17.4%
11 Bristol-Myers Squibb (BMS), United States of America (USA) 4.03 5.00 25 15.2%
12 BGI, China 6.05 4.96 27 -23.8%
13 Leidos Holdings, Inc., United States of America (USA) 3.30 4.48 69 26.3%
14 Takeda Pharmaceutical Company Limited, Japan 5.19 4.45 17 -20.2%
15 Formosa Plastics Group, Taiwan 5.27 4.16 16 -26.6%
16 Johnson & Johnson, United States of America (USA) 5.62 3.91 25 -35.4%
17 Eli Lilly and Company, United States of America (USA) 3.63 3.79 18 -2.9%
18 Sanofi, France 3.46 3.63 27 -2.5%
19 Ionis Pharmaceuticals, Inc., United States of America (USA) 3.44 3.48 20 -6.1%
20 Microsoft Corporation, United States of America (USA) 1.38 3.15 17 111.7%
21 Illumina, Inc., United States of America (USA) 3.18 3.09 15 -9.7%
22 Techint Group, Italy 2.10 2.65 13 17.6%
23 AbbVie Inc., United States of America (USA) 4.96 2.62 13 -50.9%
24 H3 Biomedicine Inc., United States of America (USA) 2.58 2.47 7 -11.2%
25 Portuguese Oncology Institute (IPO), Portugal 0.85 2.47 38 171.2%
26 Human Longevity, Inc., United States of America (USA) 3.74 2.44 8 -39.3%
27 D. E. Shaw Research, United States of America (USA) 0.08 2.30 5 2,461.4%
28 Gilead Sciences, Inc., United States of America (USA) 1.64 2.09 9 18.9%
29 Biogen Inc., United States of America (USA) 4.04 2.00 15 -53.9%
30 Corteva Agriscience, United States of America (USA) 2.00 2 N/A
31 Novo Nordisk A/S, Denmark 3.58 1.96 14 -49.2%
32 Wellspring Biosciences, United States of America (USA) 1.90 2 N/A
33 New England Biolabs, Inc. (NEB), United States of America (USA) 3.63 1.79 6 -54.1%
34 Bayer AG, Germany 1.87 1.74 27 -13.5%
35 UCB S.A., Belgium 1.59 1.73 4 1.4%
36 Merck KGaA, Germany 1.85 1.72 13 -13.5%
37 Samsung Group, South Korea 2.96 1.66 20 -47.8%
38 Agios Pharmaceuticals, Inc., United States of America (USA) 0.58 1.64 6 160.2%
39 Integral Molecular, Inc., United States of America (USA) 0.11 1.56 5 1,251.0%
40 Thermo Fisher Scientific Inc., United States of America (USA) 1.75 1.51 12 -20.1%
41 HP Inc., United States of America (USA) 1.46 3 N/A
42 GNS Science, New Zealand 0.83 1.44 6 61.0%
43 C. H. Boehringer Sohn AG & Co. KG (Boehringer Ingelheim), Germany 2.30 1.41 15 -43.2%
44 HRL Laboratories LLC, United States of America (USA) 1.13 1.40 2 15.7%
45 Sosei Co., Ltd., Japan 1.58 1.36 6 -19.7%
46 23andMe, Inc., United States of America (USA) 1.55 1.36 18 -18.6%
47 Sodercan, S.A., Spain 0.05 1.33 10 2,493.6%
48 Pacific Biosciences of California, Inc., United States of America (USA) 0.88 1.33 10 41.5%
49 Advanced Telecommunications Research Institute International (ATR), Japan 1.04 1.31 4 17.2%
50 Oxford Nanopore Technologies Ltd., United Kingdom (UK) 1.30 3 N/A

Footnote

Each year, the Nature Index publishes tables based on counts of high-quality research outputs in the previous calendar year. Users please note:

  1. The data behind the tables are based on a relatively small proportion of total research papers, they cover the natural sciences only and outputs are non-normalized (that is, they don’t reflect the size of the country or institution, or its overall research output).
  2. The Nature Index is one indicator of institutional research performance. The metrics of Count and Share used to order Nature Index listings are based on an institution’s or country’s publication output in 82 natural-science journals, selected on reputation by an independent panel of leading scientists in their fields.
  3. Nature Index recognizes that many other factors must be taken into account when considering research quality and institutional performance; Nature Index metrics alone should not be used to assess institutions or individuals.
  4. Nature Index data and methods are transparent and available under a creative commons licence at natureindex.com.

The Nature Index database undergoes regular updating, corrections, adjustment of institutional hierarchies, and removal of retracted papers and thus the live website can differ from the frozen annual tables.

*The change in adjusted Share accounts for the small annual variation in the total number of articles in Nature Index journals. Share values have been adjusted to 2020 levels to calculate the percentage change. For more information on the adjustment, please see the Adjusted metric explainer.